Jade Biosciences, Inc.
JBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001798749
No open-market purchases or sales by Jade Biosciences, Inc. insiders were filed in the last 90 days; 153 institutions reported holding it in 13F filings for Q2 2026, worth $1.62B in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Jade Biosciences, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +18 vs. Q1 2021
- Shares held
- 20.0M
- +20.0M vs. Q1 2021
- Total value
- $454.4M
- +$454.4M vs. Q1 2021
- New holders
- 18
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 153 | $1.62B |
| Q1 2026 | 120 | $700.3M |
| Q4 2025 | 105 | $726.3M |
| Q3 2025 | 78 | $272.9M |
| Q2 2025 | 75 | $315.1M |
| Q1 2025 | 82 | $79.6M |
| Q4 2024 | 80 | $79.9M |
| Q3 2024 | 75 | $57.8M |
| Q2 2024 | 81 | $45.1M |
| Q1 2024 | 81 | $841.5M |
| Q4 2023 | 64 | $637.8M |
| Q3 2023 | 58 | $386.3M |
| Q2 2023 | 60 | $488.3M |
| Q1 2023 | 66 | $524.1M |
| Q4 2022 | 70 | $802.9M |
| Q3 2022 | 56 | $447.4M |
| Q2 2022 | 51 | $403.0M |
| Q1 2022 | 46 | $475.5M |
| Q4 2021 | 47 | $301.6M |
| Q3 2021 | 41 | $452.6M |
| Q2 2021 | 18 | $454.4M |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Jade Biosciences, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kelly Financial Services LLC | 91 | $4 | 0.00% | +91 | New |
| Tower Research Capital LLC (TRC) | 235 | $5.00K | 0.00% | +235 | New |
| UBS Group AG | 2,050 | $47.0K | 0.00% | +2,050 | New |
| Squarepoint Ops LLC | 9,000 | $205.0K | 0.00% | +9,000 | New |
| Maven Securities LTD | 9,854 | $225.0K | 0.02% | +9,854 | New |
| Qube Research & Technologies Ltd | 10,500 | $240.0K | 0.00% | +10,500 | New |
| Polar Asset Management Partners Inc. | 21,070 | $481.0K | 0.01% | +21,070 | New |
| Millennium Management LLC | 65,043 | $1.49M | 0.00% | +65,043 | New |
| Goldman Sachs Group Inc | 104,755 | $2.39M | 0.00% | +104,755 | New |
| Sectoral Asset Management Inc | 500,000 | $11.4M | 0.92% | +500,000 | New |
| OrbiMed Advisors LLC | 535,714 | $12.2M | 0.12% | +535,714 | New |
| Deerfield Management Company, L.P. (Series C) | 714,285 | $16.3M | 0.29% | +714,285 | New |
| FMR LLC | 895,817 | $22.2M | 0.00% | +895,817 | New |
| Baker Bros. Advisors LP | 1,428,571 | $32.6M | 0.14% | +1,428,571 | New |
| Citadel Advisors LLC | 1,614,998 | $35.5M | 0.04% | +1,614,998 | New |
| Cormorant Asset Management, LP | 2,030,691 | $44.6M | 1.74% | +2,030,691 | New |
| Sofinnova Investments, Inc. | 3,758,686 | $85.8M | 5.21% | +3,758,686 | New |
| Ra Capital Management, L.P. | 8,263,982 | $188.7M | 3.03% | +8,263,982 | New |